We show that microRNA-21 is significantly elevated in peripheral B cells of HIV-infected individuals who go on to develop AIDS-related non-Hodgkin lymphoma (n U 13, <3 years prior to diagnosis) when compared with HIV-negative (n U 18) or HIVpositive controls (n U 21) (P < 0.01). Moreover, miR-21 is overexpressed in activated B cells and can be induced by interleukin 4 alone, or with CD40 or immunoglobulin M co-stimulation, and lipopolysaccharides, suggesting that miR-21 may help maintain B-cell hyperactivation, contributing to lymphomagenesis.
Most AIDS-related non-Hodgkin lymphomas (AIDS-NHLs) are of B-cell origin and include Burkitt's lymphoma, diffuse large B-cell lymphoma (DLBCL), primary central nervous system lymphoma (PCNSL), primary effusion lymphoma, and plasmablastic lymphomas [1] . The availability of specimens from the Multicenter AIDS Cohort Study (MACS), a large prospective longitudinal observational cohort study, allowed us to assess prediagnostic specimens for biomarkers that precede the development of such NHLs. microRNAs (miRNA) have been found to be dysregulated in most cancers [2] . Tumor-specific miRNAs have been detected in body fluids such as serum/plasma, urine, saliva (reviewed in [3] ), and cerebrospinal fluids [4] , making them attractive candidates as biomarkers that might be perturbed early in the course of disease development. miR-21 is the most commonly overexpressed miRNA in cancers. It is highly expressed in tumors arising from diverse tissue types, including brain, ovary, liver, breast, colon, lung, prostate, and stomach [5, 6] , as well as those of hematological origin, such as chronic lymphocytic leukemia [7] , DLBCL [8] , acute myeloid leukemia [9] , and Hodgkin lymphoma [10] . A recent meta-analysis of 17 independent studies assessing the prognostic role for miR-21 in various cancer types concluded that high miR-21 expression in tumors correlated with poorer prognosis, especially in digestive system and head and neck squamous cell carcinomas [11] . In contrast, higher tumor miR-21 levels were associated with better prognosis in DLBCL [8] . miR-21 can also be a diagnostic marker for PCNSL [4] or a differential diagnostic maker for DLBCL subtypes [8] . In mouse models, overexpression of miR-21 in cells of the hematopoietic lineage led to pre-B-cell lymphoma [12] , confirming the potential of miR-21 as an oncogene in B-cell malignancies.
Viably frozen peripheral blood mononuclear cells (PBMCs) from HIV-infected men who went on to develop NHL (AIDS-NHL, n ¼ 22), as well as from HIV-uninfected (n ¼ 18) and HIV-infected (n ¼ 21) men who did not develop NHL, were obtained from the MACS. AIDS-NHL individuals were separated into two groups based on whether samples were obtained less than 3 years prior (n ¼ 13) or more than 4 years prior (n ¼ 9) to NHL diagnosis. CD19 þ B cells were isolated from PBMCs, followed by total RNA extraction and miR-21 quantification by qPCR, as described [13] . Because all clinical samples were anonymized, the UCLA medical institutional review board (IRB) determined that the study was eligible for exemption from IRB review.
We found significant upregulation of miR-21 in CD19 þ B cells from AIDS-NHL patients in the 3 years prior to NHL diagnosis, when compared with either HIVinfected or HIV-uninfected groups (P < 0.01 for both comparisons), but not in AIDS-NHL patient samples obtained more than 4 years prior to NHL diagnosis (Fig. 1a ). The prediagnosis AIDS-NHL samples were comprised of the subtypes Burkitt's lymphoma (n ¼ 3), PCNSL (n ¼ 4), and DLBCL (n ¼ 6) in the less than 3 years group, and Burkitt's lymphoma (n ¼ 1), PCNSL (n ¼ 2), and DLBCL (n ¼ 6) in the more than 4 years group. We observed no correlation between B-cell Epstein-Barr virus positivity and miR-21 overexpression in these samples (data not shown). These observations indicated that miR-21 is overexpressed in circulating B cells from HIV-positive individuals who go on to develop NHL. Previously, miR-21 was also found to be elevated in serum and cerebrospinal fluid of DLBCL [14] and PCNSL [4] patients. Our observations indicate that the source of this elevated miR-21 may also include circulating B cells.
One pathway that has been suggested to be critical in lymphomagenesis is B-cell activation. In HIV-positive individuals, several B-cell stimulatory factors such as interleukin (IL) 6 [15, 16] , IL10 [16, 17] , B-lymphocyte stimulator [18] , lipopolysaccaride (LPS) [19] , and the B- 3) . The subsets were separated by FACS based on the following immunophenotype: naive (IgD þ , CD38 lo ), germinal center (IgD À , CD38 hi ), and memory (IgD À , CD38 lo ) as described [13] . Bars represent mean AE SD. P values were calculated using two-tailed t-test. cell chemokine CXCL13 [20] are elevated in the serum. Additionally, increased surface expression of TNFa on T lymphocytes [21] , and the CD40 ligand on T lymphocytes [17] and HIV virions [22, 23] , also contributes to B-cell activation. B-cell activation also occurs in secondary lymphoid organs such as lymph nodes, spleen, or tonsils following B-cell antigen encounter, and maturation via the germinal center reaction.
To explore whether miR-21 levels were differentially modulated in activated B cells, we measured miR-21 levels in tonsillar and peripheral B-cell populations, obtained from tonsillectomies (n ¼ 4) or healthy donors (n ¼ 7), respectively. We observed a 10.8-fold higher signal for miR-21 in tonsillar B cells when compared to peripheral B cells (P < 0.0001) ( Fig. 1b) . Within tonsillar B-cell subsets, we found significantly higher miR-21 expression in the germinal center (P < 0.0001) and memory (P ¼ 0.027) subsets compared with naive subsets (Fig. 1c) . Thus, miR-21 is overexpressed in activated B cells, particularly in the germinal center and memory subsets.
To further explore possible pathways for miR-21 overexpression in B cells, we utilized several molecules to activate B cells in vitro. We found significant miR-21 upregulation by stimulation with IL4 alone (P ¼ 0.002), or in combination with anti-CD40 antibody (P ¼ 0.024) or anti-immunoglobulin M (IgM) antibody (P ¼ 0.021), but not by IL6 (P ¼ 0.720) or IL10 (P ¼ 0.181) (Fig. 1d) . Although anti-CD40 or anti-IgM antibody augmented IL4-induced miR-21 expression, they were insufficient for miR-21 induction, suggesting that the helper T-cell produced cytokine IL4 is important for miR-21 upregulation.
Previously, it was shown that B cells express the LPS receptor CD14 and are functionally responsive to LPS [24] . Direct stimulation of B cells by LPS did not change miR-21 levels ( Fig. 1d ; LPS, P ¼ 0.340); however, when LPS was added to whole PBMC [ Fig. 1d ; LPS (PBMC)], it significantly induced miR-21 overexpression in B cells (P ¼ 0.021), suggesting a role for activated monocytes and T cells in B-cell miR-21 upregulation.
Overall, these data suggest that miR-21 overexpression is a consequence of B-cell activation seen in HIV infection, with a shift to a germinal center phenotype among circulating B cells. Increased appearance of circulating B cells with germinal center or immature/transitional phenotype [25] is a feature of HIV disease progression. The phenotype of cells contributing to increased miR-21 expression in AIDS-NHL remains to be defined. In summary, elevated levels of the B-cell activation-induced miR-21 in circulating B cells are seen in those persons who go on to develop AIDS-NHL, suggesting that miR-21 may be an important biomarker for assessing NHL risk in HIV-infected individuals.
